 | | Vol. 13.18 – 10 May, 2022 |
| |
|
|
LncRNA-PACERR Induces Pro-Tumor Macrophages via Interacting with miR-671-3p and m6A-Reader IGF2BP2 in Pancreatic Ductal Adenocarcinoma | Scientists found the function and molecular mechanism of PACERR in tissue-associated macrophages to regulate PDAC progression.
[Journal of Hematology & Oncology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
Glutathione Prevents High Glucose-Induced Pancreatic Fibrosis by Suppressing Pancreatic Stellate Cell Activation via the ROS/TGFβ/SMAD Pathway | To explore the role of glutathione in pancreatic fibrosis and β-cell failure induced by hyperglycaemia, researchers established a rat model of pancreatic fibrosis and β-cell failure.
[Cell Death & Disease] |
|
|
|
NR5A2/LRH-1 Regulates the PTGS2-PGE2-PTGER1 Pathway Contributing to Pancreatic Islet Survival and Function | The authors defined the role of LRH-1 in postnatal islet morphogenesis and charted the BL001 mode of action confering beta-cell protection.
[iScience] |
|
|
|
Exosomal miR-140–3p and miR-143–3p from TGF-β1-Treated Pancreatic Stellate Cells Target BCL2 mRNA to Increase β-Cell Apoptosis | MiRNAs packaged as exosomes are the key regulators of β-cell dysfunction. Researchers defined the effect of exosomal miRNA from activated pancreatic stellate cells on β-cells.
[Molecular and Cellular Endocrinology] |
| |
|
|
ISL2 Is a Putative Tumor Suppressor Whose Epigenetic Silencing Reprograms the Metabolism of Pancreatic Cancer | Through in vivo CRISPR screening, scientists discovered islet-2 (ISL2) as a candidate tumor suppressor that modulated aggressive PDAC growth.
[Developmental Cell] |
|
|
|
Cytoglobin Attenuates Pancreatic Cancer Growth via Scavenging Reactive Oxygen Species | Investigators examined the role of cytoglobin in the development of pancreatic cancer. Its expression appeared predominately in the area surrounding adenocarcinoma and negatively correlated with tumor size in patients with pancreatic cancer.
[Oncogenesis] |
|
|
|
MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2 Associated Cell Adhesion | Scientists observed that MUC16 and its C-terminal expression was significantly high in human PDAC tissues, PDAC organoids, and metastatic liver tissues, while no expression was observed in normal pancreatic tissues.
[Molecular Cancer Research] |
|
|
|
FAM126A Interacted with ENO1 Mediates Proliferation and Metastasis in Pancreatic Cancer via PI3K/AKT Signaling Pathway | Based on the Gene Expression Omnibus, the Gene Expression Profiling Interactive Analysis, researchers observed that family sequence similarity (FAM) 126A was in high expressed levels among pancreatic cancer (PC) tissues and contributed to worse progression of PC.
[Cell Death Discovery] |
|
|
|
Starvation Mediates Pancreatic Cancer Cell Sensitivity to Ferroptosis via ERK1/2, JNK and Changes in the Cell Mesenchymal State | The authors examined the prospects of a novel approach to kill pancreatic cancer cells: starvation combined with ferroptosis induction.
[International Journal of Molecular Medicine] |
|
|
|
|
Altered Glycosylation in Pancreatic Cancer and Beyond | The functionality of glycans as they contribute to hallmarks of PDAC are highlighted as active regulators of disease onset, tumor progression, metastatic capability, therapeutic resistance, and remodeling of the tumor immune microenvironment.
[Journal of Experimental Medicine] |
|
|
|
The Interactive Role of Inflammatory Mediators and Metabolic Reprogramming in Pancreatic Cancer | Investigators focus on the interactive role of inflammatory signaling and metabolic reprogramming with emerging evidence of crosstalk, which supports the development, progression, and therapeutic resistance of PDAC.
[Trends in Cancer] |
|
|
|
|
ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase III Program with Partner Tonghua Dongbao | Adocia announced the dosing of the first patient with the BioChaperone® Lispro Phase III study. The Phase III program consists of 2 studies treating people with type 1 and type 2 diabetes in 100 clinical centers across China and will enroll a total of 1300 patients.
[Adocia SA] |
|
|
|
Agastiya Biotech Receives FDA Orphan Drug Designation for AB001 for Pancreatic Cancer and Acute Myeloid Leukemia (AML) | Agastiya Biotech and Vopec Pharmaceuticals announce that the US FDA has granted Orphan Drug Designations for Pancreatic Cancer and AML for its novel small molecule, AB001.
[Agastiya Biotech (Cision US, Inc.)] |
|
|
|
|
| November 10 – 12, 2022
Bordeaux, France |
|
|
|
|
|
| | Cincinnati Childrens – Cincinnati, Ohio, United States |
|
|
|
| | Sidney Kimmel Cancer Center – Philadelphia, Pennsylvania, United States |
|
|
|
|
| | Vanderbilt University – Nashville, Tennessee, United States |
|
|
|
| | Johns Hopkins University School of Medicine – St. Petersburg, Florida, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
